Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug

RemeGen’s Disitamab Vedotin Phase III Study Meets PFS and OS Endpoints

Fineline Cube May 13, 2025

China-based RemeGen Ltd (HKG: 9995) announced that its Phase III clinical study for the antibody...

Company Deals

Eastenova Biotechnology Makes Hong Kong IPO Debut With Regenerative Medicine Focus

Fineline Cube May 13, 2025

China-based Eastenova (Chengdu) Biotechnology Co., Ltd. this week made an initial public offering (IPO) to...

Company Drug

AstraZeneca’s Trixeo Aerosphere Wins UK Approval for COPD

Fineline Cube May 13, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced this week that it has received marketing...

Company Drug

Grand Pharma Completes Patient Enrollment for TLX591-CDx Phase III Trial

Fineline Cube May 13, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) announced the completion of patient enrollment for the Phase...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Clearance for SHR-1316 (sc) in ES-SCLC Trial

Fineline Cube May 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...

Company Drug

Fosun Pharma’s LBP-ShC4 Receives FDA Approval for Androgenic Alopecia Study

Fineline Cube May 12, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that it has...

Company Medical Device

MicroPort’s Talos Stent Gains Marketing Approval in Argentina

Fineline Cube May 12, 2025

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval...

Policy / Regulatory

Hainan Unveils 20 Measures to Boost Pharmaceutical Industry Reform and Quality

Fineline Cube May 12, 2025

The General Office of the People’s Government of Hainan Province has released the “Implementation Plan...

Company Deals

Minghui Pharmaceutical Signs Licensing Deal with Qilu for B7-H3 ADC Development

Fineline Cube May 12, 2025

China-based Minghui Pharmaceutical has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical....

Company Deals

EnChannel Medical Secures RMB 600 Million in Series B Funding for Electrophysiological Products

Fineline Cube May 12, 2025

China-based EnChannel Medical Guangzhou Inc., a specialist in electrophysiology, has reportedly secured RMB 600 million...

Company Drug

Hansoh Pharma’s Ameile Wins Fourth NMPA Approval for NSCLC Treatment

Fineline Cube May 12, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its epidermal growth factor receptor...

Company Deals

Eli Lilly and Purdue Expand Partnership With $250 Million Investment

Fineline Cube May 12, 2025

US-based Eli Lilly & Co. (NYSE: LLY) and Purdue University have expanded their long-term partnership...

Company Drug

CARsgen Therapeutics’ CT0596 Shows Promising Results in Early Clinical Study

Fineline Cube May 12, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced preliminary clinical data for CT0596, an allogeneic...

Company Drug

CSPC Receives FDA Approval for SYH2046 in Heart Failure After Acute Myocardial Infarction

Fineline Cube May 12, 2025

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company Drug

UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG

Fineline Cube May 12, 2025

Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from Japan’s Pharmaceuticals and...

Company Deals Drug

Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development

Fineline Cube May 12, 2025

China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding...

Company Drug

InnoCare Pharma’s Mesutoclax Granted Breakthrough Therapy Designation for R/R MCL

Fineline Cube May 12, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation...

Company

AstraZeneca Breaks Ground on New Small Molecule Drug Plant in Wuxi

Fineline Cube May 12, 2025

UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has commenced the construction of a new small...

Company Drug

IASO Biotherapeutics’ Fucaso Granted Orphan Drug Designation by SFDA for Multiple Myeloma

Fineline Cube May 12, 2025

China-based IASO Biotherapeutics announced that the Saudi Food and Drug Authority (SFDA) has granted Orphan...

Company Drug

Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity

Fineline Cube May 12, 2025

China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions,...

Posts pagination

1 … 217 218 219 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.